TipRanksStock Market NewsAnalysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Imugene (OtherIUGNF)

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF) and Imugene (OtherIUGNF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Siemens Healthineers AG (SEMHFResearch Report) and Imugene (IUGNFResearch Report) with bullish sentiments.

Siemens Healthineers AG (SEMHF)

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Siemens Healthineers AG, with a price target of EUR75.00. The company’s shares closed last Wednesday at $70.60.

Friedrichs has an average return of 10.9% when recommending Siemens Healthineers AG.

According to TipRanks.com, Friedrichs is ranked #1775 out of 7771 analysts.

Currently, the analyst consensus on Siemens Healthineers AG is a Moderate Buy with an average price target of $77.91, implying a 10.4% upside from current levels. In a report issued on January 3, J.P. Morgan also maintained a Buy rating on the stock with a EUR77.50 price target.

See Insiders’ Hot Stocks on TipRanks >>

Imugene (IUGNF)

Noble Financial analyst Robert LeBoyer maintained a Buy rating on Imugene today and set a price target of $0.50. The company’s shares closed last Wednesday at $0.28.

According to TipRanks.com, LeBoyer is a 4-star analyst with an average return of 25.4% and a 36.1% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Onconova Therapeutics, and PDS Biotechnology.

Imugene has an analyst consensus of Moderate Buy, with a price target consensus of $0.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SEMHF:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More